Strata Critical Medical (SRTA) Co‑CEO Melissa Tomkiel Receives Award

What Happened
Melissa M. Tomkiel, Co‑CEO, General Counsel and director of Strata Critical Medical (SRTA), had performance‑based restricted stock units (PSUs) convert into 177,858 shares on 2026‑09‑24 (acquired at $0). To satisfy tax withholding obligations on the vesting, the company withheld 90,797 of those shares at $5.27 each, resulting in proceeds of $478,500 (disposed). Net shares retained from the vesting: 87,061 (177,858 acquired − 90,797 withheld).

Key Details

• Transaction date: 2026‑09‑24; filing date: 2026‑09‑25.
• Award/acquisition: 177,858 shares (code A), acquisition price reported as $0 (PSU vesting).
• Tax withholding/disposition: 90,797 shares (code F) at $5.27 per share, proceeds $478,500.
• Shares owned after transaction: not specified in this filing.
• Footnotes: F1 — shares issued upon certification that performance criteria were met for PSUs granted 8/29/2026; F2 — shares were withheld to satisfy tax withholding on vesting.
• Filing appears to report the transaction promptly (transactions dated 9/24/2026; report filed 9/25/2026).

Context: This was a performance‑based equity award vesting, not an open‑market purchase. The withheld shares are a common, routine way employers satisfy tax obligations on vested equity (similar to a cashless withholding) and do not necessarily indicate the insider is selling additional shares for personal reasons.